Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Revenue (2016 - 2025)

ImmunityBio (IBRX) has disclosed Revenue for 12 consecutive years, with $38.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 406.95% to $38.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $113.3 million, a 668.31% increase, with the full-year FY2025 number at $113.3 million, up 668.31% from a year prior.
  • Revenue was $38.3 million for Q4 2025 at ImmunityBio, up from $32.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $38.3 million in Q4 2025 to a low of $14000.0 in Q1 2022.
  • A 5-year average of $6.5 million and a median of $239000.0 in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: plummeted 89.93% in 2022, then skyrocketed 41192.5% in 2025.
  • ImmunityBio's Revenue stood at $390000.0 in 2021, then crashed by 81.28% to $73000.0 in 2022, then skyrocketed by 90.41% to $139000.0 in 2023, then skyrocketed by 5333.09% to $7.6 million in 2024, then skyrocketed by 406.95% to $38.3 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Revenue are $38.3 million (Q4 2025), $32.1 million (Q3 2025), and $26.4 million (Q2 2025).